J&J’s nipocalimab racks up another win, this time in Sjögren’s disease
17 Jun 2024
Clinical ResultAcquisitionPhase 3Phase 2Post-Marketing Study
Johnson & Johnson reported interim Phase II data for nipocalimab showing that the anti-FcRn antibody helped improve symptoms of Sjögren’s disease versus placebo. The data were shared at the European Alliance of Associations for Rheumatology (EULAR) annual meeting on Saturday.
In the DAHLIAS study, adults with Sjögren’s disease who received 15 mg/kg nipocalimab every two weeks had a more than 70% average improvement in ClinESSDAIa score versus placebo at 24 weeks. The pharma said the monoclonal antibody (mAb) also led to statistically significant and clinically meaningful reductions in disease severity compared with patients’ baseline score on the composite ClinESSDAIa scale, which assesses disease activity across 11 organ system domains.
Additionally, nipocalimab showed benefits on several key secondary endpoints, although J&J did not specify whether they were statistically significant. The results of multiple organ and physician assessments were “clinically meaningful,” and patients saw “improvement trends” on several Sjögren’s symptoms including mouth dryness, eye dryness, and vaginal dryness.
The mAb also lowered levels of IgG and disease-related autoantibodies, supporting its mechanism of action. The pharma said that nipocalimab’s safety and tolerability were consistent with other trials.
Autoantibody disease portfolio
Sjögren’s is the third disease that nipocalimab has found clinical success with since J&J gained the compound in 2020 via its $6.5-billion acquisition of Momenta Therapeutics.
Last year, the antibody met the primary endpoint of a Phase II trial of pregnant adults at high risk for severe haemolytic disease of the foetus and newborn. The pharma is also working with RallyBio to reduce the risk of foetal neonatal alloimmune thrombocytopenia.
Earlier this year, J&J said it was preparing to seek approval of nipocalimab to treat generalised myasthenia gravis after the mAb met the primary endpoint of the Phase III VIVACITY study.
According to its website, the pharma is also running mid-stage studies of nipocalimab in rheumatoid arthritis, systemic lupus erythematosus, warm autoimmune haemolytic anaemia and idiopathic inflammatory myopathy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.